The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19. Issue 3 (14th July 2022)

• Record Type: Journal Article
• Authors: Hu, Qing; Xiong, Yuan; Zhu, Guang‐Hao; Zhang, Ya‐Ni; Zhang, Yi‐Wen; Huang, Ping; Ge, Guang‐Bo
• Is Part Of: MedComm. Volume 3:Issue 3(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-07-14
• Subjects: 3‐chymotrypsin‐like protease (3CLpro) -- broad‐spectrum anti‐coronavirus agents -- SARS‐CoV‐2 -- β‐coronavirus 3CLpro inhibitor; 610
• DOI: 10.1002/mco2.151
• Languages: English
• ISSNs: 2688-2663

Abstract

Abstract: The main proteases (M pro ), also termed 3‐chymotrypsin‐like proteases (3CL pro ), are a class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has demonstrated that 3CL pro s play an indispensable role in viral replication and have been recognized as key targets for preventing and treating coronavirus‐caused infectious diseases, including COVID‐19. This review is focused on the structural features and biological function of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) main protease M pro (also known as 3CL pro ), as well as recent advances in discovering and developing SARS‐CoV‐2 3CL pro inhibitors. To better understand the characteristics of SARS‐CoV‐2 3CL pro inhibitors, the inhibition activities, inhibitory mechanisms, and key structural features of various 3CL pro inhibitors (including marketed drugs, peptidomimetic, and non‐peptidomimetic synthetic compounds, as well as natural compounds and their derivatives) are summarized comprehensively. Meanwhile, the challenges in this field are highlighted, while future directions for designing and developing efficacious 3CL pro inhibitors as novel anti‐coronavirus therapies are also proposed. Collectively, all information and knowledge presented here are very helpful for understanding the structural features and inhibitory mechanisms of SARS‐CoV‐2 3CL pro inhibitors, which offers new insights or inspiration to medicinal chemists for designing and developing more efficacious 3CL pro inhibitors as novel anti‐coronavirus agents. Abstract : A comprehensive summary of recent advances in SARS‐CoV‐2 3CL pro inhibitors (including marketed drugs, peptidomimetic, and non‐peptidomimetic synthetic compounds, as well as natural compounds and their derivatives), including the inhibitory activities, inhibitory mechanisms, and key structural features, provides new insights for designing and developing more efficacious 3CL pro inhibitors as broad‐spectrum anti‐coronavirus agents.